Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 318

Showing 1-25 of 318 citing articles:

Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Despoina Chrysostomou, Lauren A. Roberts, Julian R. Marchesi, et al.
Gastroenterology (2022) Vol. 164, Iss. 2, pp. 198-213
Open Access | Times Cited: 141
Interplay of oxidative stress, cellular communication and signaling pathways in cancer
Muhammad Javed Iqbal, Ayesha Kabeer, Zaighum Abbas, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 137
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 133
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 122
The use of RNA-based treatments in the field of cancer immunotherapy
Mohammad Chehelgerdi, Matin Chehelgerdi
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 90
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 77
Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy
Xufeng Lu, Xiaohong Chen, Chengyin Lin, et al.
Advanced Science (2024) Vol. 11, Iss. 18
Open Access | Times Cited: 65
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Mateusz Kciuk, Esam Bashir Yahya, Montaha Mohamed Ibrahim Mohamed, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2721-2721
Open Access | Times Cited: 60
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1143-1143
Open Access | Times Cited: 55
Cuprous oxide nanocomposites with photothermal (PTT) and chemical dynamics (CDT) effects induce cuproptosis in breast cancer using the strategy of increasing inflow and reducing outflow
Wei Li, Yao Xiao, Guohu Guo, et al.
Nano Today (2024) Vol. 56, pp. 102223-102223
Open Access | Times Cited: 26
Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy
Yelee Kim, Jiwoong Choi, Eun Hye Kim, et al.
Advanced Science (2024) Vol. 11, Iss. 22
Open Access | Times Cited: 20
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics
Tosin Akinsipe, Rania Mohamedelhassan, Ayuba Akinpelu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 18
Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE
S Liu, Nan Zhang, Xu Ji, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Helminth extracellular vesicles co‐opt host monocytes to drive T cell anergy
Anne Borup, Mohammad Farouq Sharifpour, Litten Sørensen Rossen, et al.
Journal of Extracellular Vesicles (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Demystifying the Role of Immuno PET-CT in Non-Small Cell Lung Cancer: Clinical Value and Research Trends
Sobhan Vinjamuri, Vineet Pant
Seminars in Nuclear Medicine (2025)
Closed Access | Times Cited: 2
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access | Times Cited: 2
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 66
Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
Long Ma, Jixiang Ma, Muzhou Teng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 57
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Alain E. Andrea, Andrada Chiron, Sarah Mallah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals
Olga O. Krasnovskaya, Daniil Abramchuck, Alexander S. Erofeev, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9154-9154
Open Access | Times Cited: 25
Ligand-based active targeting strategies for cancer theranostics
Anupriya Bandyopadhyay, Tuyelee Das, Samapika Nandy, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 12, pp. 3417-3441
Closed Access | Times Cited: 25
Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor
Ling-Yan Su, Yang Tian, Qiang Zheng, et al.
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1219-1230.e5
Closed Access | Times Cited: 16
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Wonyoung Jo, Taejoon Won, Abdel Daoud, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy
Haojun Wang, Quanwei Zhou, Ding Fang Xie, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 12
Antitumor Research Based on Drug Delivery Carriers: Reversing the Polarization of Tumor-Associated Macrophages
Xinyu Cao, Shen Wan, Bingyu Wu, et al.
Molecular Pharmaceutics (2025)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top